Literature DB >> 22054142

Psoriasis.

Gayathri K Perera1, Paola Di Meglio, Frank O Nestle.   

Abstract

Psoriasis is a common relapsing and remitting immune-mediated inflammatory disease that affects the skin and joints. This review focuses on current immunogenetic concepts, key cellular players, and axes of cytokines that are thought to contribute to disease pathogenesis. We highlight potential therapeutic targets and give an overview of the currently used immune-targeted therapies.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22054142     DOI： 10.1146/annurev-pathol-011811-132448

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN： 1553-4006            Impact factor:   23.472


  172 in total

1.  miR-203 promotes HaCaT cell overproliferation through targeting LXR-α and PPAR-γ.

Authors:  Yueyuan Xiao; Haizhen Wang; Chang Wang; Bijun Zeng; Xueyong Tang; Yujin Zhang; Youhua Peng; Meijunzi Luo; Pan Huang; Zhibo Yang
Journal:  Cell Cycle       Date:  2020-06-28       Impact factor: 4.534

2.  Computational Systems Biology of Psoriasis: Are We Ready for the Age of Omics and Systems Biomarkers?

Authors:  Tuba Sevimoglu; Kazim Yalcin Arga
Journal:  OMICS       Date:  2015-10-19

Review 3.  CD4+ T-cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm.

Authors:  Kiyoshi Hirahara; Toshinori Nakayama
Journal:  Int Immunol       Date:  2016-02-12       Impact factor: 4.823

Review 4.  IL-17 family: cytokines, receptors and signaling.

Authors:  Chunfang Gu; Ling Wu; Xiaoxia Li
Journal:  Cytokine       Date:  2013-09-03       Impact factor: 3.861

5.  Isoliquiritigenin prevents the progression of psoriasis-like symptoms by inhibiting NF-κB and proinflammatory cytokines.

Authors:  Yangping Wu; Xiangzheng Chen; Xiaojun Ge; Hongwei Xia; Yuxi Wang; Siyuan Su; Wenting Li; Tinghan Yang; Mingtian Wei; Hang Zhang; Lantu Gou; Jiong Li; Xian Jiang; Jinliang Yang
Journal:  J Mol Med (Berl)       Date:  2015-09-18       Impact factor: 4.599

Review 6.  The Potential Role of Inhibitory Receptors in the Treatment of Psoriasis.

Authors:  Neha Shah; Sabina Sandigursky; Adam Mor
Journal:  Bull Hosp Jt Dis (2013)       Date:  2017-05

7.  IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms.

Authors:  Hye-Lin Ha; Hongshan Wang; Prapaporn Pisitkun; Jin-Chul Kim; Ilaria Tassi; Wanhu Tang; Maria I Morasso; Mark C Udey; Ulrich Siebenlist
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

Review 8.  Immunology of psoriasis.

Authors:  Michelle A Lowes; Mayte Suárez-Fariñas; James G Krueger
Journal:  Annu Rev Immunol       Date:  2014       Impact factor: 28.527

9.  IL-4 abrogates T(H)17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells.

Authors:  Emmanuella Guenova; Yuliya Skabytska; Wolfram Hoetzenecker; Günther Weindl; Karin Sauer; Manuela Tham; Kyu-Won Kim; Ji-Hyeon Park; Ji Hae Seo; Desislava Ignatova; Antonio Cozzio; Mitchell P Levesque; Thomas Volz; Martin Köberle; Susanne Kaesler; Peter Thomas; Reinhard Mailhammer; Kamran Ghoreschi; Knut Schäkel; Boyko Amarov; Martin Eichner; Martin Schaller; Rachael A Clark; Martin Röcken; Tilo Biedermann
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

10.  Dry eye and tear film functions in patients with psoriasis.

Authors:  Young Her; Ji Won Lim; Sang Hak Han
Journal:  Jpn J Ophthalmol       Date:  2013-03-23       Impact factor: 2.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.